<DOC>
	<DOCNO>NCT00685802</DOCNO>
	<brief_summary>The purpose study evaluate compare relative bioavailability test formulation cilostazol tablet equivalent dose Pletal速 ( cilostazol ) tablets single oral dose administer fasting condition .</brief_summary>
	<brief_title>Fasted Bioavailability Study Cilostazol Tablets , 50mg</brief_title>
	<detailed_description>The purpose study evaluate compare relative bioavailability test formulation cilostazol tablet equivalent dose Pletal速 ( cilostazol ) tablets single oral dose administer fasting condition . Thirty-two non-smoking , non-obese , healthy male female volunteer age 18 55 randomly assign crossover fashion receive two cilostazol dose regimen sequence 7 day washout period dose period . On morning Day 1 , overnight fast least 10 hour , subject receive either single oral dose test formulation , cilostazol ( 2 x 50 mg tablet ) , single oral dose reference formulation , Pletal速 ( 2 x 50 mg tablet ) . After 7 day washout period morning Day 8 , follow overnight fast least 10 hour , subject receive alternate regimen . Blood sample draw participant dose 24 hour post-dose confined basis time sufficient adequately define pharmacokinetics cilostazol . Blood sample continue non-confined basis 36 48 hour post-dose . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout confinement portion study adverse reaction study drug and/or procedure . Blood pressure pulse measure dose 3 24 hour post-dose . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate investigator report subject 's case report form .</detailed_description>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Healthy adult 1855 year age Nonsmoking Nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) No 15 % plus minus ideal weight subject 's height elbow breadth define Metropolitan Life Insurance Company Statistical Bulletin . Extrapolations , require , conduct accord BASi Standard Operating Procedures Medically healthy basis medical history physical examination within 30 day prior start study Test result blood chemistry , hematology , urinalysis perform within 30days prior start study within clinically acceptable limit At screening , subject must blood pressure pulse rate within follow range : Systolic blood pressure 90140mmHg ; Diastolic blood pressure 5090mmHg ; Pulse 45100 bpm An acceptable electrocardiogram ( EKG ) : sinus rhythm evidence AV block ischemic change Prescription drug use ( exclude hormonal contraceptive ) within 14 day prior drug administration , period Aspirin ingestion within 7 day prior drug administration , period Use overthecounter preparation , herbal remedy , and/or nutritional supplement within 7 day prior drug administration , period Consumption grapefruit juice grapefruitcontaining product within 72 hour prior drug administration , period Consumption alcohol within 24 hour prior drug administration , period Consumption caffeine within 10 hour prior drug administration , period Female subject must pregnant nursing ; must surgically sterile ; one year postmenopausal ; hormonal contraceptive agent ( ) , diaphragm condom spermicidal foam jelly , IUD least three month prior drug administration agree use method contraception least 1 month last drug administration Subjects history presence significant organ system ( cardiovascular , neurological , hepatic , hematopoietic , renal , pulmonary , endocrine , gastrointestinal ) disorder , ongoing infectious disease History hypersensitivity adverse reaction cilostazol ( Pletal速 ) , relate drug Recent ( 12 month ) history evidence alcoholism drug abuse Positive urine screen drug abuse Positive result Human Immunodeficiency Virus ( HIV ) Hepatitis B surface Antigen ( HBsAg ) test Participation another clinical trial previous 30 day day 1 study Donation blood previous 30 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>